Restifo N P
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Curr Opin Immunol. 1996 Oct;8(5):658-63. doi: 10.1016/s0952-7915(96)80082-3.
Whereas cancer cells are poor immunogens, some viruses are capable of eliciting powerful and lifelong immunity. Recombinant viruses and plasmid DNA encoding tumor-associated antigens can elicit powerful and specific immune responses that can be enhanced by the use of cytokines and costimulatory molecules. These immune responses have destroyed growing tumor cells in experimental animal models. For the first time, immunotherapeutic strategies that employ recombinant viruses are being tested in clinical trials with cancer patients.
癌细胞是弱免疫原，而一些病毒能够引发强大且持久的免疫反应。编码肿瘤相关抗原的重组病毒和质粒DNA可引发强大而特异的免疫反应，利用细胞因子和共刺激分子可增强这些反应。在实验动物模型中，这些免疫反应已摧毁了正在生长的肿瘤细胞。首次采用重组病毒的免疫治疗策略正在癌症患者的临床试验中进行测试。
